

(Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting:

**Time and Date:** 8 a.m.–5 p.m., May 3, 2012 (Closed).

**Place:** Sheraton Gateway Hotel Atlanta Airport, 1900 Sullivan Road, Atlanta, Georgia 30337, Telephone: (770) 997–1100.

**Status:** The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463.

**Matters To Be Discussed:** The meeting will include the initial review, discussion, and evaluation of applications received in response to “Identifying Reasons for Racial/Ethnic Disparities with Completing the HPV Vaccine Series among Adolescent Females, FOA IP12–004; and Intervention Study to Increase Use of Standing Orders Programs for Vaccinating Adults in Physician Office Settings, FOA IP12–005.”

**Contact Person for More Information:** Gregory Anderson, M.S., M.P.H., Scientific Review Officer, CDC, 1600 Clifton Road NE., Mailstop E60, Atlanta, Georgia 30333, Telephone: (404) 718–8833.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: January 25, 2012.

**Elaine L. Baker,**

*Director, Management Analysis and Services Office Centers for Disease Control and Prevention.*

[FR Doc. 2012–2143 Filed 1–31–12; 8:45 am]

**BILLING CODE 4163–18–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Administration for Children and Families

#### Tribal Consultation Meetings

**AGENCY:** Administration for Children and Families’ Office of Head Start (OHS).

**ACTION:** Notice of meetings.

**SUMMARY:** Pursuant to the Improving Head Start for School Readiness Act of 2007, Public Law 110–134, notice is hereby given of a one-day Tribal Consultation Session to be held between the Department of Health and Human Services, Administration for Children and Families, Office of Head Start leadership and the leadership of Tribal Governments operating Head Start (including Early Head Start) programs. The purpose of this Consultation Session is to discuss ways to better meet

the needs of American Indian and Alaska Native children and their families, taking into consideration funding allocations, distribution formulas, and other issues affecting the delivery of Head Start services in their geographic locations [42 U.S.C. 9835, Section 640(l)(4)].

**DATES:** February 15, 2012.

**ADDRESSES:** 2012 Office of Head Start Tribal Consultation Session will be held at the following location:

Wednesday, February 15, 2012—Petoskey, Michigan—Odawa Hotel, 1444 US 131 South, Petoskey, MI 49770.

**FOR FURTHER INFORMATION CONTACT:** Camille Loya, Acting Regional Program Manager Region XI, email [Camille.Loya@acf.hhs.gov](mailto:Camille.Loya@acf.hhs.gov) or phone (202) 401–5964. Additional information and online meeting registration is available at <http://www.headstartresourcecenter.org>.

**SUPPLEMENTARY INFORMATION:** The Department of Health and Human Services (HHS) announces Office of Head Start (OHS) Tribal Consultations with leaders of Tribal Governments operating Head Start (including Early Head Start) programs for each of the nine geographic regions of Head Start where AI/AN programs are located. We are convening the OHS Tribal Consultations in conjunction with other Tribal Leader events in order to minimize the financial and travel burden for participants. The session in Petoskey, Michigan, is being held in conjunction with the U.S. Department of Health and Human Services and Midwest Alliance of Sovereign Tribes 2012 Midwest Tribal Consultation Session. We will schedule additional consultations around the country for later in the year.

The agenda for the scheduled OHS Tribal Consultation will be organized around the statutory purposes of Head Start Tribal Consultations related to meeting the needs of American Indian and Alaska Native children and families, taking into consideration funding allocations, distribution formulas, and other issues affecting the delivery of Head Start services in their geographic locations. In addition, OHS will share actions taken and in progress to address the issues and concerns raised in 2011 OHS Tribal Consultations.

Tribal leaders and designated representatives interested in submitting written testimony or proposing specific agenda topics for this Consultation Session should contact Camille Loya at [Camille.Loya@acf.hhs.gov](mailto:Camille.Loya@acf.hhs.gov). Proposals must be submitted at least three days in advance of the session and should

include a brief description of the topic area, along with the name and contact information of the suggested presenter.

The Consultation Session will be conducted with elected or appointed leaders of Tribal Governments and their designated representatives [42 U.S.C. 9835, Section 640(l)(4)(A)]. Designees must have a letter from the Tribal Government authorizing them to represent the tribe. The letter should be submitted at least three days in advance of the Consultation Session to Camille Loya at (202) 205–9721 (fax). Other representatives of tribal organizations and Native nonprofit organizations are welcome to attend as observers.

A detailed report of each Consultation Session will be prepared and made available within 90 days of the Consultation Session to all Tribal Governments receiving funds for Head Start and Early Head Start programs. Tribes wishing to submit written testimony for the report should send testimony to Camille Loya at [Camille.Loya@acf.hhs.gov](mailto:Camille.Loya@acf.hhs.gov) either prior to the Consultation Session or within 30 days after the meeting.

Oral testimony and comments from the Consultation Session will be summarized in the report without attribution, along with topics of concern and recommendations. Hotel and logistical information for all Consultation Sessions has been sent to tribal leaders via email and posted on the Head Start Resource Center Web site at <http://www.headstartresourcecenter.org>.

Dated: January 24, 2012.

**Yvette Sanchez Fuentes,**  
*Director, Office of Head Start.*

[FR Doc. 2012–2166 Filed 1–31–12; 8:45 am]

**BILLING CODE 4184–40–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA–2009–N–0247]

#### Food and Drug Administration Transparency Initiative: Exploratory Program To Increase Access to the Agency’s Compliance and Enforcement Data; Availability

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing the availability of a report entitled “Food and Drug Administration Transparency Initiative: Exploratory Program to

Increase Access to the Agency's Compliance and Enforcement Data," as part of the Transparency Initiative. This report includes eight initiatives adopted by the Commissioner of Food and Drugs (the Commissioner) to explore avenues for making FDA's publicly available compliance and enforcement data more accessible and user-friendly.

**FOR FURTHER INFORMATION CONTACT:**

Daniel W. Sigelman, Office of the Commissioner, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, rm. 4254, Silver Spring, MD 20993, 301-796-4706, Fax: 301-847-8616, email: [daniel.sigelman@fda.hhs.gov](mailto:daniel.sigelman@fda.hhs.gov).

**SUPPLEMENTARY INFORMATION:** FDA is announcing the availability of a report entitled "Food and Drug Administration Transparency Initiative: Exploratory Program to Increase Access to the Agency's Compliance and Enforcement Data." FDA is responsible for a broad range of compliance and enforcement activities. Increasing the transparency of these activities enhances the public's understanding of the Agency's decisions and promotes accountability of the Agency and the regulated industry.

In a May 6, 2011, memorandum to the Department of Health and Human Services responding to a January 18, 2011, Presidential Memorandum on Regulatory Compliance, (76 FR 3825, January 21, 2011), FDA recounted the actions it had already implemented, as well as those proposed or underway, to increase public accessibility of its regulatory compliance and enforcement information. FDA stated that it would: (1) Issue proposals for public comment within 150 days (by October 3, 2011) if

it concluded that there were additional opportunities to increase the transparency of its compliance and enforcement data, and (2) determine within 270 days (by January 31, 2012) whether to adopt such proposals.

On October 3, 2011, FDA issued a report entitled "Food and Drug Administration Transparency Initiative: Draft Proposals for Public Comment to Increase Transparency by Promoting Greater Access to the Agency's Compliance and Enforcement Data," that advanced eight draft proposals to make FDA's publicly available compliance and enforcement data more accessible and user-friendly (<http://www.fda.gov/downloads/AboutFDA/Transparency/TransparencyInitiative/UCM273145.pdf>). In publishing a notice of availability of this report on October 4, 2011 (76 FR 61366), FDA sought public comment on these proposals by December 2, 2011. The Agency stated that its Transparency Task Force would ultimately recommend specific draft proposals to the Commissioner for consideration based on the comments it received, the feasibility of each draft proposal, relative priority, and available resources, and that the Commissioner would determine whether to adopt any of these draft proposals by January 31, 2012.

Based on a review of the recommendations of the Transparency Task Force, the Commissioner is adopting all eight of the draft proposals published in October 2011 as initiatives the Agency will explore, thereby committing the Agency to investigating numerous avenues for increasing the transparency and public accessibility of its compliance and enforcement data.

Dated: January 27, 2012.

**David Dorsey,**

*Acting Associate Commissioner for Policy and Planning.*

[FR Doc. 2012-2184 Filed 1-31-12; 8:45 am]

**BILLING CODE 4160-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA-2011-N-0003]

### Withdrawal of Approval of New Animal Drug Applications

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is withdrawing approval of 20 new animal drug applications (NADAs) at the sponsor's request because the products are no longer manufactured or marketed.

**DATES:** Withdrawal of approval is effective February 13, 2012.

**FOR FURTHER INFORMATION CONTACT:** John Bartkowiak, Center for Veterinary Medicine (HFV-212), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-276-9079, email: [john.bartkowiak@fda.hhs.gov](mailto:john.bartkowiak@fda.hhs.gov).

**SUPPLEMENTARY INFORMATION:** The following sponsors have requested that FDA withdraw approval of the 20 NADAs listed in table 1 of this document because the products are no longer manufactured or marketed:

TABLE 1—NADAs FOR WHICH APPROVAL IS VOLUNTARILY WITHDRAWN

Application No.	Trade name (drug)	Applicant
NADA 014-485 .....	METOPHANE Inhalation (methoxyflurane) .....	Medical Developments, International Ltd., 556 Morris Ave., Summit, NJ 07901-1330.
NADA 032-322 .....	LIQUISONE F with Cerumene (hexamethyltetraacosane, prednisolone, tetracaine, neomycin sulfate).	Evsco Pharmaceuticals, an Affiliate of IGI, Inc., Box 209, Harding Hwy., Buena, NJ 08310.
NADA 044-655 .....	NEOMYCANE Ophthalmic Ointment (neomycin sulfate) .....	Evsco Pharmaceuticals, an Affiliate of IGI, Inc., Box 209, Harding Hwy., Buena, NJ 08310.
NADA 045-288 .....	OPTISONE (neomycin sulfate, prednisolone acetate) .....	Evsco Pharmaceuticals, an Affiliate of IGI, Inc., Box 209, Harding Hwy., Buena, NJ 08310.
NADA 049-890 .....	NORCO T-2 Pre-Pak (tylosin phosphate) .....	Norco Mills of Norfolk, Inc., P.O. Box 56, Norfolk, NE 68701.
NADA 055-034 .....	CHLORASOL (chloramphenicol) .....	Evsco Pharmaceuticals, an Affiliate of IGI, Inc., Box 209, Harding Hwy., Buena, NJ 08310.
NADA 055-052 .....	Chlora-Tabs 100 (chloramphenicol) .....	Evsco Pharmaceuticals, an Affiliate of IGI, Inc., Box 209, Harding Hwy., Buena, NJ 08310.
NADA 065-158 .....	CHLORICOL (chloramphenicol) .....	Evsco Pharmaceuticals, An Affiliate of IGI, Inc., Box 209, Harding Hwy., Buena, NJ 08310.
NADA 065-259 .....	CHLORASONE Ophthalmic Ointment (chloramphenicol, prednisolone acetate).	Evsco Pharmaceuticals, an Affiliate of IGI, Inc., Box 209, Harding Hwy., Buena, NJ 08310.
NADA 065-488 .....	BENZA-PEN (penicillin G benzathine, penicillin G procaine)	Walco International, Inc., 15 West Putnam, Porterville, CA 93257.